Executive Summary
This batch of 21 new federal contracts totals $3.6B in obligations, with 17 bullish signals dominated by long-term health R&D, border security construction, and IT/cybersecurity services, providing revenue visibility through 2047. Public companies like SAIC ($446.8M across two awards), Fluor, General Dynamics IT, Northrop Grumman, Ameresco, and CoreCivic capture ~15% of value with options upside averaging 40% above obligations.
Firm fixed price structures prevail (70% of contracts), flagging execution risks amid low average outlays (22% of obligated).
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from March 12, 2026.
Investment Signals (4)
- Border security construction acceleration (HIGH)▲
DHS awards $560.9M border wall (Barnard Spencer JV) and $128M detention services (CoreCivic, Akima) signal sustained infrastructure spend through 2028.
- Health IT and cybersecurity ramp-up (HIGH)▲
HHS/CMS awards $245M+ to Iron Vine, SparkSoft, Porter Novelli for cyber ops, provider screening, and Medicare campaigns, with 50%+ outlays indicating momentum.
- SAIC engineering dominance (HIGH)▲
SAIC secures $446.8M across GSA orders for battlefield engineering and IT sustainment, with options to $593M ceiling.
- Long-term contract execution overhang (MEDIUM)▲
11 contracts span 7+ years to 2047, with average outlay just 22% of obligations, risking delays.
Risk Flags (3)
- Execution [HIGH RISK]▼
Firm fixed price on 70% of contracts ($2.6B) exposes winners to cost overruns, especially long-term builds like border wall and embassies.
- Market [MEDIUM RISK]▼
Low average outlays (22%, or $793M disbursed of $3.6B) across awards signal potential funding delays tied to fiscal cycles.
- Regulatory [MEDIUM RISK]▼
Geopolitical exposure in foreign projects (e.g., Turkmenistan embassy) and disaster-tied FEMA work risks scope changes.
Opportunities (3)
- ◆
Unexercised options average 40% uplift ($1.4B potential) on 14 contracts, e.g., Frontier Technology SBIR to $553M.
- ◆
Federal energy retrofits and deep energy programs through 2047 align with ESG mandates, $111.9M award to Ameresco.
- ◆
Small/disadvantaged businesses (8 awards, $745M) winning full/open comp via set-asides position for repeat DHS/HHS work.
Sector Themes (3)
- ◆
HHS leads with $1.2B (33% of total) in biotech, clinical ops, Medicare IT, often via nonprofits/small biz but with long horizons to 2031.
- ◆
$821M (23%) in border wall, detention, disaster support through 2028 reflects policy-driven security spend.
- ◆
GSA/VA awards $650M+ for engineering, service desks, radar support emphasize multi-year O&M contracts.
Watch List (4)
- 👁
{"entity"=>"SAIC", "reason"=>"$446.8M obligations with $130M options; repeated GSA wins signal franchise strength.", "trigger"=>"Q4 earnings subaward details or option exercises"}
- 👁
{"entity"=>"CoreCivic", "reason"=>"$57M ICE detention award amid border focus; non-competed status hints at incumbency.", "trigger"=>"2025 outlays >20% or follow-on Krome/Cal City extensions"}
- 👁
{"entity"=>"Ameresco", "reason"=>"23-year $112M energy retrofit with $54M options; aligns with federal sustainability push.", "trigger"=>"initial outlays or GSA Round 7 awards"}
- 👁
{"entity"=>"Fluor Federal Services", "reason"=>"$134M FEMA disaster order with $102M options; Florida hurricane tie-in offers quick revenue.", "trigger"=>"outlay acceleration post-2025 storms"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 21 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals